FY2025 · ended Sep 30, 2025 · Revenue $1.41M, -82.6% YoY · Filed Dec 19, 2025
Outlook Therapeutics, Inc. (OTLK) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Sep 30, 2025, it reported revenue of $1.4 million and a net loss of $62.4 million. As of Jun 30, 2026 it held $11.2 million in cash and investments and $204,144 in total debt.
Revenue
$1.41M
-82.6% vs prior year
Net income
$-62.42M
+17.2% vs prior year
Operating cash flow (TTM)
$-56.15M
+0.5% vs year-ago TTM
Free cash flow
$-32.73M
+8.6% vs prior year
EPS
$-1.79
+55.9% vs prior year
Dividend per share
None
Shares outstanding
64.11M
+100.5% vs prior year
Net cash
$11.04M
as of Jun 30, 2026
Operating margin
-4744.3%
FY 2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- OTLK (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- Iselin, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1649989
- Former names
- Oncobiologics, Inc. (until Nov 13, 2018)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Sep 30, 2025 |
FY 2024 Sep 30, 2024 |
FY 2023 Sep 30, 2023 |
FY 2022 Sep 30, 2022 |
FY 2021 Sep 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.4M | — | — | — | — |
| Operating income | -$67.1M | -$71.7M | -$53.1M | -$63.1M | -$51.7M |
| Net income | -$62.4M | -$75.4M | -$59.0M | -$66.1M | -$53.2M |
| Diluted EPS | -$1.79 | -$4.06 | -$4.72 | -$0.31 | -$0.35 |
| Operating cash flow | -$51.8M | -$68.8M | -$43.0M | -$56.7M | -$54.3M |
| Total assets | $18.6M | $28.8M | $32.3M | $28.5M | $22.8M |
| Total liabilities | $50.8M | $101.9M | $46.7M | $19.8M | $18.2M |
| Stockholders' equity | -$32.2M | -$73.1M | -$14.4M | $8.7M | $4.6M |
| Cash and investments | $8.1M | $14.9M | $23.4M | $17.4M | $14.5M |
| Total debt | $247,698 | $297,829 | $4,267 | $43,013 | $112,331 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Sep 30, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Other events
|
Sep 18, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 27, 2026 | Aug 23, 2026 |
| 10-Q | Quarterly report | Aug 18, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Aug 14, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
All 833 Outlook Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.